Literature DB >> 12576026

Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL).

Nobuhiko Kayagaki1, Noriko Yamaguchi, Masaaki Abe, Sachiko Hirose, Toshikazu Shirai, Ko Okumura, Hideo Yagita.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL), a type II membrane protein belonging to the TNF family, induces apoptotic cell death in various types of tumor cells. However, little is known about its pathological and physiological functions in the immune system. In this study, we showed that administration of neutralizing anti-TRAIL mAb markedly increased serum auto-Ab levels, particularly of IgG1 subclass, in autoimmune-prone C3H/HeJ gld/gld mice without affecting lymphocytosis and lymphocytes populations. In an experimental system where TNP-specific Ab production was induced by immunization with TNP-modified syngeneic B lymphoma cells, expression of TRAIL on these cells significantly reduced TNP-specific Ab production, especially of IgG1 subclass, without affecting T cell priming. These results suggest a new role for TRAIL in the suppression of Ab production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12576026     DOI: 10.1016/s0008-8749(02)00602-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 2.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

3.  Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.

Authors:  Lisa M Sedger; Arna Katewa; Ann K Pettersen; Sarah R Osvath; Geoff C Farrell; Graeme J Stewart; Linda J Bendall; Stephen I Alexander
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

4.  An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Hsiu-Jung Liao; Chien-Sheng Wu; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2017-04-10       Impact factor: 11.530

5.  Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.

Authors:  Claire L Dobson; Sarah Main; Philip Newton; Matthieu Chodorge; Karen Cadwallader; Robin Humphreys; Vivian Albert; Tristan J Vaughan; Ralph R Minter; Bryan M Edwards
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

6.  TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects.

Authors:  Vinh Nguyen; Cornelia Cudrici; Valentina Zernetkina; Florin Niculescu; Horea Rus; Cynthia Drachenberg; Violeta Rus
Journal:  Clin Immunol       Date:  2009-04-05       Impact factor: 3.969

Review 7.  Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review.

Authors:  Takashi Ohnishi; Yuki Ogawa; Kota Suda; Miki Komatsu; Satoko Matsumoto Harmon; Mitsuru Asukai; Masahiko Takahata; Norimasa Iwasaki; Akio Minami
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 8.  TRAIL modulates the immune system and protects against the development of diabetes.

Authors:  Fleur Bossi; Stella Bernardi; Giorgio Zauli; Paola Secchiero; Bruno Fabris
Journal:  J Immunol Res       Date:  2015-02-18       Impact factor: 4.818

Review 9.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

10.  Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.

Authors:  Sébastien S Dufresne; Antoine Boulanger-Piette; Sabrina Bossé; Anteneh Argaw; Dounia Hamoudi; Laetitia Marcadet; Daniel Gamu; Val A Fajardo; Hideo Yagita; Josef M Penninger; A Russell Tupling; Jérôme Frenette
Journal:  Acta Neuropathol Commun       Date:  2018-04-24       Impact factor: 7.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.